Tin Su
Concepts (402)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drosophila melanogaster | 31 | 2026 | 236 | 7.970 |
Why?
| | Drosophila Proteins | 26 | 2026 | 212 | 6.940 |
Why?
| | Drosophila | 19 | 2026 | 166 | 4.600 |
Why?
| | Radiation, Ionizing | 15 | 2026 | 87 | 4.300 |
Why?
| | Regeneration | 8 | 2026 | 197 | 2.970 |
Why?
| | Apoptosis | 19 | 2026 | 2430 | 2.780 |
Why?
| | Cell Cycle | 17 | 2020 | 596 | 2.030 |
Why?
| | Wings, Animal | 9 | 2026 | 37 | 1.700 |
Why?
| | Imaginal Discs | 6 | 2026 | 6 | 1.570 |
Why?
| | Mitosis | 12 | 2011 | 200 | 1.510 |
Why?
| | Caspases | 4 | 2020 | 232 | 1.440 |
Why?
| | DNA Damage | 15 | 2020 | 430 | 1.430 |
Why?
| | Neoplasms | 9 | 2026 | 2875 | 1.320 |
Why?
| | Animals | 68 | 2026 | 38058 | 1.260 |
Why?
| | Wnt1 Protein | 3 | 2022 | 8 | 1.210 |
Why?
| | Cell Cycle Proteins | 11 | 2017 | 628 | 1.130 |
Why?
| | Tumor Suppressor Protein p53 | 6 | 2020 | 529 | 1.090 |
Why?
| | Cell Plasticity | 2 | 2026 | 37 | 1.070 |
Why?
| | Vaccines | 2 | 2023 | 389 | 1.070 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2025 | 48 | 1.040 |
Why?
| | STAT Transcription Factors | 2 | 2017 | 24 | 1.010 |
Why?
| | Morphogenesis | 3 | 2026 | 173 | 0.990 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2026 | 22 | 0.990 |
Why?
| | High-Throughput Screening Assays | 2 | 2023 | 175 | 0.970 |
Why?
| | Larva | 9 | 2026 | 242 | 0.960 |
Why?
| | Malaysia | 10 | 2026 | 16 | 0.920 |
Why?
| | Stem Cells | 3 | 2018 | 626 | 0.910 |
Why?
| | Chromosomes | 3 | 2024 | 108 | 0.900 |
Why?
| | Protein Biosynthesis | 3 | 2025 | 458 | 0.890 |
Why?
| | Loss of Heterozygosity | 2 | 2024 | 52 | 0.860 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 275 | 0.860 |
Why?
| | Autophagy | 3 | 2026 | 286 | 0.850 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2026 | 219 | 0.850 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2194 | 0.840 |
Why?
| | Head and Neck Neoplasms | 3 | 2025 | 558 | 0.830 |
Why?
| | Cell Death | 5 | 2018 | 383 | 0.800 |
Why?
| | Radiation Tolerance | 3 | 2014 | 103 | 0.790 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2015 | 43 | 0.790 |
Why?
| | Hematologic Neoplasms | 1 | 2025 | 161 | 0.770 |
Why?
| | Spindle Apparatus | 7 | 2011 | 105 | 0.770 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 79 | 0.770 |
Why?
| | Cell Phone | 2 | 2026 | 82 | 0.750 |
Why?
| | Models, Biological | 11 | 2020 | 1821 | 0.730 |
Why?
| | Drug Discovery | 2 | 2023 | 155 | 0.720 |
Why?
| | DNA Replication | 4 | 2010 | 251 | 0.680 |
Why?
| | Embryo, Nonmammalian | 6 | 2011 | 173 | 0.670 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 463 | 0.660 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2021 | 459 | 0.660 |
Why?
| | Gene Expression Profiling | 2 | 2022 | 1782 | 0.650 |
Why?
| | Wound Healing | 1 | 2023 | 351 | 0.640 |
Why?
| | DNA Repair | 6 | 2020 | 256 | 0.620 |
Why?
| | Transcription Factors | 4 | 2022 | 1741 | 0.620 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 321 | 0.610 |
Why?
| | Text Messaging | 1 | 2022 | 182 | 0.610 |
Why?
| | Glioblastoma | 1 | 2023 | 353 | 0.610 |
Why?
| | Peptide Hydrolases | 1 | 2020 | 105 | 0.610 |
Why?
| | Salivary Glands | 1 | 2019 | 36 | 0.590 |
Why?
| | Gastrula | 3 | 2004 | 17 | 0.580 |
Why?
| | Drugs, Investigational | 1 | 2019 | 31 | 0.580 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 194 | 0.560 |
Why?
| | Signal Transduction | 8 | 2026 | 5226 | 0.560 |
Why?
| | Epithelial Cells | 3 | 2026 | 1125 | 0.550 |
Why?
| | DNA-Binding Proteins | 8 | 2026 | 1499 | 0.530 |
Why?
| | Pyrophosphatases | 1 | 2017 | 25 | 0.530 |
Why?
| | Breast Neoplasms | 4 | 2024 | 2452 | 0.530 |
Why?
| | Teaching | 2 | 2011 | 236 | 0.520 |
Why?
| | E2F1 Transcription Factor | 2 | 2024 | 68 | 0.520 |
Why?
| | Nuclear Proteins | 4 | 2009 | 748 | 0.520 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 928 | 0.510 |
Why?
| | Gene Expression Regulation, Developmental | 7 | 2022 | 905 | 0.500 |
Why?
| | Microtubule-Associated Proteins | 2 | 2009 | 196 | 0.490 |
Why?
| | Telemedicine | 2 | 2023 | 945 | 0.480 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.470 |
Why?
| | Humans | 49 | 2026 | 144759 | 0.470 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4557 | 0.450 |
Why?
| | Protein Kinases | 5 | 2021 | 315 | 0.450 |
Why?
| | MicroRNAs | 2 | 2014 | 701 | 0.440 |
Why?
| | Quality of Life | 3 | 2026 | 3185 | 0.430 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 191 | 0.430 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2009 | 433 | 0.420 |
Why?
| | Phosphorylation | 8 | 2025 | 1732 | 0.420 |
Why?
| | Research | 1 | 2017 | 431 | 0.420 |
Why?
| | Methyl Methanesulfonate | 3 | 2010 | 7 | 0.420 |
Why?
| | Mutation | 13 | 2020 | 4089 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1263 | 0.400 |
Why?
| | Heterozygote | 3 | 2024 | 315 | 0.390 |
Why?
| | Mutagens | 3 | 2010 | 26 | 0.390 |
Why?
| | Cell Lineage | 3 | 2026 | 376 | 0.370 |
Why?
| | RNA Interference | 4 | 2026 | 476 | 0.370 |
Why?
| | Genome, Insect | 1 | 2012 | 28 | 0.360 |
Why?
| | Neuropeptides | 2 | 2009 | 77 | 0.360 |
Why?
| | Climate Change | 2 | 2026 | 199 | 0.360 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3540 | 0.350 |
Why?
| | Cross-Sectional Studies | 8 | 2026 | 5868 | 0.350 |
Why?
| | Chromosome Aberrations | 2 | 2024 | 162 | 0.350 |
Why?
| | Cell Survival | 5 | 2024 | 1098 | 0.350 |
Why?
| | Students | 2 | 2023 | 663 | 0.350 |
Why?
| | Cell Proliferation | 7 | 2025 | 2496 | 0.340 |
Why?
| | Cyclin A | 2 | 2001 | 18 | 0.340 |
Why?
| | Cancer Vaccines | 2 | 2025 | 160 | 0.340 |
Why?
| | Maytansine | 1 | 2011 | 18 | 0.340 |
Why?
| | Embryo, Mammalian | 2 | 2023 | 232 | 0.340 |
Why?
| | DNA, Satellite | 1 | 2010 | 18 | 0.330 |
Why?
| | E2F2 Transcription Factor | 1 | 2010 | 14 | 0.330 |
Why?
| | Hydrozoa | 1 | 2010 | 2 | 0.330 |
Why?
| | Paclitaxel | 1 | 2012 | 255 | 0.330 |
Why?
| | Cell Division | 3 | 2005 | 766 | 0.330 |
Why?
| | Membrane Proteins | 1 | 2017 | 1166 | 0.320 |
Why?
| | Educational Measurement | 2 | 2011 | 326 | 0.320 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 187 | 0.320 |
Why?
| | Adjuvants, Immunologic | 2 | 2023 | 245 | 0.320 |
Why?
| | Heterochromatin | 1 | 2010 | 67 | 0.310 |
Why?
| | Piperazines | 2 | 2024 | 381 | 0.310 |
Why?
| | Biology | 1 | 2011 | 91 | 0.310 |
Why?
| | Peer Group | 2 | 2011 | 257 | 0.310 |
Why?
| | Cell Differentiation | 3 | 2026 | 2050 | 0.300 |
Why?
| | Genetics | 1 | 2009 | 23 | 0.290 |
Why?
| | Tyrosine | 1 | 2009 | 222 | 0.290 |
Why?
| | Leprosy | 2 | 2019 | 25 | 0.280 |
Why?
| | CDC2 Protein Kinase | 3 | 2005 | 27 | 0.280 |
Why?
| | Learning | 2 | 2011 | 452 | 0.270 |
Why?
| | Cyclin E | 2 | 2007 | 23 | 0.270 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1266 | 0.270 |
Why?
| | Metaphase | 3 | 2005 | 33 | 0.270 |
Why?
| | Anaphase | 3 | 2005 | 20 | 0.270 |
Why?
| | Immunotherapy | 2 | 2025 | 653 | 0.270 |
Why?
| | Cell Movement | 2 | 2019 | 965 | 0.260 |
Why?
| | Reactive Oxygen Species | 2 | 2026 | 621 | 0.230 |
Why?
| | Genes, cdc | 3 | 2006 | 11 | 0.230 |
Why?
| | Mice | 9 | 2025 | 18339 | 0.230 |
Why?
| | Ecological Momentary Assessment | 1 | 2026 | 45 | 0.230 |
Why?
| | Gene Expression Regulation | 3 | 2009 | 2608 | 0.220 |
Why?
| | Chromosomal Instability | 1 | 2004 | 21 | 0.210 |
Why?
| | Telomere | 2 | 2006 | 288 | 0.210 |
Why?
| | Cisplatin | 2 | 2024 | 334 | 0.210 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2026 | 192 | 0.210 |
Why?
| | MAP Kinase Signaling System | 3 | 2024 | 310 | 0.210 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2004 | 17 | 0.210 |
Why?
| | Tubulin | 1 | 2005 | 147 | 0.210 |
Why?
| | Peroxiredoxins | 1 | 2024 | 26 | 0.210 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2003 | 4 | 0.200 |
Why?
| | Alleles | 3 | 2020 | 879 | 0.200 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2024 | 47 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 167 | 0.200 |
Why?
| | Arthropods | 1 | 2004 | 16 | 0.200 |
Why?
| | Mental Disorders | 2 | 2026 | 1168 | 0.200 |
Why?
| | Adjuvants, Pharmaceutic | 1 | 2023 | 15 | 0.200 |
Why?
| | Radioimmunotherapy | 1 | 2023 | 22 | 0.200 |
Why?
| | Curriculum | 1 | 2011 | 1059 | 0.200 |
Why?
| | Pyrimidinones | 1 | 2024 | 126 | 0.200 |
Why?
| | Vertebrates | 1 | 2004 | 67 | 0.200 |
Why?
| | Flow Cytometry | 3 | 2022 | 1173 | 0.200 |
Why?
| | Organogenesis | 1 | 2003 | 65 | 0.190 |
Why?
| | Exercise | 2 | 2026 | 2201 | 0.190 |
Why?
| | Telomere-Binding Proteins | 1 | 2004 | 119 | 0.190 |
Why?
| | Albumins | 1 | 2023 | 118 | 0.190 |
Why?
| | Embryonic Stem Cells | 1 | 2023 | 130 | 0.190 |
Why?
| | Cytoskeleton | 1 | 2004 | 195 | 0.190 |
Why?
| | Indonesia | 1 | 2022 | 23 | 0.190 |
Why?
| | Vietnam | 1 | 2022 | 30 | 0.190 |
Why?
| | Antigens, Neoplasm | 2 | 2025 | 271 | 0.190 |
Why?
| | Gene Expression | 2 | 2018 | 1490 | 0.190 |
Why?
| | Bangladesh | 1 | 2022 | 62 | 0.190 |
Why?
| | Pyridones | 1 | 2024 | 199 | 0.190 |
Why?
| | Immunoprecipitation | 3 | 2009 | 151 | 0.180 |
Why?
| | Review Literature as Topic | 1 | 2022 | 53 | 0.180 |
Why?
| | Cell Line | 4 | 2023 | 2882 | 0.180 |
Why?
| | Cell Separation | 2 | 2022 | 307 | 0.180 |
Why?
| | India | 1 | 2022 | 218 | 0.180 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2001 | 71 | 0.170 |
Why?
| | Microscopy, Confocal | 4 | 2007 | 321 | 0.170 |
Why?
| | Neurofibromin 2 | 2 | 2021 | 3 | 0.170 |
Why?
| | Checkpoint Kinase 2 | 4 | 2010 | 27 | 0.170 |
Why?
| | Telephone | 1 | 2022 | 175 | 0.170 |
Why?
| | Escherichia coli Infections | 1 | 2022 | 129 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2026 | 684 | 0.160 |
Why?
| | Prevalence | 3 | 2023 | 2834 | 0.160 |
Why?
| | Food Services | 1 | 2020 | 21 | 0.160 |
Why?
| | Blotting, Western | 4 | 2009 | 1187 | 0.160 |
Why?
| | Lymph Nodes | 1 | 2023 | 502 | 0.160 |
Why?
| | Cetuximab | 1 | 2020 | 111 | 0.160 |
Why?
| | Intracellular Space | 1 | 2020 | 66 | 0.160 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 53 | 0.160 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 36 | 0.160 |
Why?
| | Phthalazines | 1 | 2020 | 64 | 0.160 |
Why?
| | Poverty | 1 | 2024 | 529 | 0.160 |
Why?
| | Feeding Behavior | 1 | 2026 | 684 | 0.150 |
Why?
| | Pyridines | 1 | 2024 | 605 | 0.150 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2020 | 186 | 0.150 |
Why?
| | Neoplastic Stem Cells | 2 | 2023 | 412 | 0.150 |
Why?
| | Female | 17 | 2026 | 78271 | 0.150 |
Why?
| | Biological Evolution | 1 | 2004 | 488 | 0.150 |
Why?
| | Diacylglycerol Kinase | 1 | 2019 | 5 | 0.150 |
Why?
| | Perception | 1 | 2022 | 377 | 0.150 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2023 | 370 | 0.150 |
Why?
| | rac GTP-Binding Proteins | 1 | 2019 | 34 | 0.150 |
Why?
| | DNA | 2 | 2005 | 1463 | 0.150 |
Why?
| | Mental Health | 1 | 2026 | 790 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 421 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 1137 | 0.150 |
Why?
| | Radiobiology | 1 | 2019 | 7 | 0.150 |
Why?
| | Embryonic Development | 1 | 2000 | 125 | 0.140 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 132 | 0.140 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2000 | 167 | 0.140 |
Why?
| | Molecular Imaging | 1 | 2019 | 55 | 0.140 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2018 | 153 | 0.140 |
Why?
| | Checkpoint Kinase 1 | 4 | 2006 | 27 | 0.140 |
Why?
| | Pandemics | 2 | 2024 | 1694 | 0.140 |
Why?
| | Phenotype | 3 | 2018 | 3162 | 0.130 |
Why?
| | Transients and Migrants | 1 | 2017 | 27 | 0.130 |
Why?
| | S Phase | 2 | 2010 | 80 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 442 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 6048 | 0.130 |
Why?
| | Gene Silencing | 2 | 2016 | 205 | 0.130 |
Why?
| | Escherichia coli | 1 | 2022 | 854 | 0.130 |
Why?
| | Rural Population | 1 | 2022 | 650 | 0.130 |
Why?
| | Protein Transport | 1 | 2018 | 441 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1135 | 0.120 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 20 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2023 | 780 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 375 | 0.120 |
Why?
| | Cell Polarity | 1 | 2017 | 137 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2019 | 4154 | 0.120 |
Why?
| | Receptors, TIE | 1 | 2015 | 1 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1966 | 0.110 |
Why?
| | Cost of Illness | 1 | 2017 | 321 | 0.110 |
Why?
| | Genetic Testing | 1 | 2017 | 478 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3409 | 0.110 |
Why?
| | Adult | 6 | 2024 | 40449 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 2 | 2005 | 370 | 0.100 |
Why?
| | Qualitative Research | 1 | 2022 | 1671 | 0.100 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 269 | 0.100 |
Why?
| | HeLa Cells | 1 | 2015 | 650 | 0.100 |
Why?
| | Time Factors | 5 | 2005 | 7173 | 0.100 |
Why?
| | Middle Aged | 4 | 2024 | 35875 | 0.100 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 123 | 0.100 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 140 | 0.090 |
Why?
| | X-Rays | 2 | 2004 | 31 | 0.090 |
Why?
| | Male | 10 | 2026 | 72315 | 0.090 |
Why?
| | Biomarkers | 2 | 2026 | 4271 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 845 | 0.090 |
Why?
| | Drug Synergism | 2 | 2024 | 357 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 24 | 0.090 |
Why?
| | Brain | 1 | 2004 | 2933 | 0.080 |
Why?
| | Embryology | 1 | 2011 | 1 | 0.080 |
Why?
| | HCT116 Cells | 1 | 2011 | 78 | 0.080 |
Why?
| | Tuberous Sclerosis | 1 | 2011 | 56 | 0.080 |
Why?
| | Glioma | 1 | 2015 | 425 | 0.080 |
Why?
| | Mice, Nude | 2 | 2024 | 682 | 0.080 |
Why?
| | Mitotic Index | 1 | 2010 | 25 | 0.080 |
Why?
| | Cyclins | 2 | 2001 | 84 | 0.080 |
Why?
| | Drug Design | 1 | 2011 | 173 | 0.080 |
Why?
| | Young Adult | 3 | 2022 | 14105 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 758 | 0.080 |
Why?
| | Aged | 4 | 2026 | 25913 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2022 | 8265 | 0.080 |
Why?
| | Green Fluorescent Proteins | 2 | 2008 | 405 | 0.080 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 143 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 2155 | 0.070 |
Why?
| | Cell Nucleus | 2 | 2003 | 618 | 0.070 |
Why?
| | Goals | 1 | 2011 | 183 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2026 | 1095 | 0.070 |
Why?
| | Molecular Sequence Data | 2 | 2003 | 2930 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2009 | 381 | 0.070 |
Why?
| | Biological Products | 1 | 2012 | 252 | 0.070 |
Why?
| | Gene Deletion | 2 | 2015 | 389 | 0.070 |
Why?
| | Kinetochores | 1 | 2008 | 52 | 0.070 |
Why?
| | China | 2 | 2019 | 269 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1382 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2168 | 0.070 |
Why?
| | Xenopus | 2 | 2005 | 89 | 0.070 |
Why?
| | Gene Dosage | 1 | 2008 | 148 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 152 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1720 | 0.060 |
Why?
| | E2F Transcription Factors | 1 | 2007 | 62 | 0.060 |
Why?
| | Comprehension | 1 | 2009 | 180 | 0.060 |
Why?
| | Cytokinesis | 1 | 2007 | 50 | 0.060 |
Why?
| | Adolescent | 5 | 2026 | 22428 | 0.060 |
Why?
| | Nanoparticles | 2 | 2025 | 519 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1318 | 0.060 |
Why?
| | Healthy Aging | 1 | 2026 | 40 | 0.060 |
Why?
| | Gastrin-Releasing Peptide | 1 | 2005 | 6 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2005 | 416 | 0.060 |
Why?
| | Chromatography, Affinity | 1 | 2005 | 85 | 0.060 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 110 | 0.060 |
Why?
| | Centrosome | 1 | 2005 | 71 | 0.060 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2006 | 56 | 0.060 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 7 | 0.050 |
Why?
| | Transgenes | 1 | 2005 | 189 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2006 | 766 | 0.050 |
Why?
| | Models, Genetic | 2 | 2006 | 536 | 0.050 |
Why?
| | DNA Repair Enzymes | 1 | 2004 | 29 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2004 | 69 | 0.050 |
Why?
| | Melanoma, Experimental | 1 | 2025 | 108 | 0.050 |
Why?
| | Cleavage Stage, Ovum | 1 | 2004 | 5 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2004 | 93 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 824 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2024 | 135 | 0.050 |
Why?
| | Egg Proteins | 1 | 2004 | 20 | 0.050 |
Why?
| | Invertebrates | 1 | 2004 | 24 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2832 | 0.050 |
Why?
| | Retinoblastoma Protein | 1 | 2004 | 61 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 79 | 0.050 |
Why?
| | Gene Targeting | 1 | 2004 | 82 | 0.050 |
Why?
| | Endoderm | 1 | 2023 | 21 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2004 | 36 | 0.050 |
Why?
| | Macaca fascicularis | 1 | 2023 | 71 | 0.050 |
Why?
| | Fertilization | 1 | 2004 | 44 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2004 | 224 | 0.050 |
Why?
| | Glycosyltransferases | 1 | 2023 | 16 | 0.050 |
Why?
| | Models, Anatomic | 1 | 2004 | 84 | 0.050 |
Why?
| | X Chromosome | 1 | 2003 | 67 | 0.050 |
Why?
| | Crosses, Genetic | 1 | 2003 | 124 | 0.050 |
Why?
| | Substrate Specificity | 1 | 2004 | 388 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2023 | 246 | 0.050 |
Why?
| | Body Patterning | 1 | 2004 | 138 | 0.050 |
Why?
| | Africa | 1 | 2023 | 116 | 0.050 |
Why?
| | Accelerometry | 1 | 2024 | 119 | 0.050 |
Why?
| | Protective Factors | 1 | 2023 | 99 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2003 | 366 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 983 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 396 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 124 | 0.050 |
Why?
| | DNA Transposable Elements | 1 | 2003 | 122 | 0.050 |
Why?
| | Mammals | 1 | 2004 | 293 | 0.050 |
Why?
| | Recombination, Genetic | 1 | 2003 | 205 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2005 | 750 | 0.040 |
Why?
| | Telomerase | 1 | 2004 | 248 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2003 | 570 | 0.040 |
Why?
| | Fertility | 1 | 2003 | 168 | 0.040 |
Why?
| | 14-3-3 Proteins | 1 | 2001 | 15 | 0.040 |
Why?
| | beta-Lactamases | 1 | 2022 | 51 | 0.040 |
Why?
| | Insect Proteins | 1 | 2001 | 40 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 477 | 0.040 |
Why?
| | Health Surveys | 1 | 2023 | 518 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2001 | 224 | 0.040 |
Why?
| | Cytoplasm | 1 | 2001 | 269 | 0.040 |
Why?
| | Plasmids | 1 | 2022 | 379 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 1 | 2005 | 579 | 0.040 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 22 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2020 | 85 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2022 | 370 | 0.040 |
Why?
| | Temperature | 1 | 2004 | 679 | 0.040 |
Why?
| | Ubiquitination | 1 | 2021 | 118 | 0.040 |
Why?
| | Virulence Factors | 1 | 2022 | 172 | 0.040 |
Why?
| | Mass Media | 1 | 2020 | 41 | 0.040 |
Why?
| | Blastoderm | 1 | 2000 | 1 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 15 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 266 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 163 | 0.040 |
Why?
| | Proteolysis | 1 | 2021 | 173 | 0.040 |
Why?
| | Health Education | 1 | 2023 | 358 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Biological Factors | 1 | 2020 | 39 | 0.040 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2000 | 65 | 0.040 |
Why?
| | Cell Size | 1 | 2000 | 92 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1716 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2023 | 441 | 0.040 |
Why?
| | Base Sequence | 1 | 2003 | 2190 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2000 | 151 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 289 | 0.040 |
Why?
| | Heat-Shock Response | 1 | 2000 | 78 | 0.040 |
Why?
| | Cell Count | 1 | 2000 | 320 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 126 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 205 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 2027 | 0.040 |
Why?
| | Phylogeny | 1 | 2003 | 1016 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 881 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2025 | 917 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 521 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 237 | 0.030 |
Why?
| | Histones | 1 | 2004 | 669 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 264 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 969 | 0.030 |
Why?
| | Cognition | 1 | 2026 | 1266 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 199 | 0.030 |
Why?
| | Microscopy | 1 | 2019 | 156 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 627 | 0.030 |
Why?
| | Schools | 1 | 2020 | 453 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2004 | 3121 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2020 | 499 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1495 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2015 | 11 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2000 | 553 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1837 | 0.030 |
Why?
| | Child | 2 | 2026 | 22633 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2273 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1455 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1953 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1496 | 0.030 |
Why?
| | Health Promotion | 1 | 2020 | 774 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5992 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1982 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1414 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1907 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 10779 | 0.010 |
Why?
| | Xenopus Proteins | 1 | 2005 | 37 | 0.010 |
Why?
| | G2 Phase | 1 | 2005 | 39 | 0.010 |
Why?
| | Hydroxyurea | 1 | 2005 | 34 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 276 | 0.010 |
Why?
| | RNA-Binding Proteins | 1 | 2006 | 462 | 0.010 |
Why?
| | RNA | 1 | 2005 | 940 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|